In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak-Reference-Cited by-同舟云学术

In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhu YanChun¹,Kilburn Shannon¹,Kapoor Mili²,Chaturvedi Sudha¹³,Shaw Karen Joy⁴,Chaturvedi Vishnu¹³^ORCID

Affiliation:

1. Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA

2. Amplyx Pharmaceuticals, San Diego, California, USA

3. Department of Biomedical Sciences, University at Albany School of Public Health, Albany, New York, USA

4. Hearts Consulting Group, Poway, California, USA

Abstract

An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used broad-spectrum antifungal drugs, and that several isolates are panresistant. Thus, there is an urgent need for new drugs with a novel mechanism of action to combat the resistance challenge. Manogepix (MGX) is a first-in-class agent that targets the fungal Gwt1 enzyme.

Funder

Amplyx Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01124-20

Reference41 articles.

1. Candida auris in Healthcare Facilities, New York, USA, 2013–2017

2. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016

3. Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses